Impact of SLC43A3/ENBT1 expression and function on 6-mercaptopurine transport and cytotoxicity in human acute lymphoblastic leukemia cells

Nicholas M. Ruel*, Khanh Hoa Nguyen*, Chan S. Kim, Laura P. S. Andrade, & James R. Hammond

* Co-first authors

Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7
RUNNING TITLE PAGE

a) Running Title: ENBT1-mediated 6-mercaptopurine uptake by leukemia cells

b) Corresponding author:

Dr James R Hammond

Department of Pharmacology

9-70 Medical Sciences Building

University of Alberta

Edmonton, AB, T6G 2H7, Canada

Email: james.hammond@ualberta.ca

Tel: 780-492-3414    Fax: 780-492-4325

c) Text pages = 34

Tables = 1

Figures = 8

References = 34

Abstract = 244 words

Introduction = 611 words

Discussion = 910 words
d) Abbreviations

6-MP – 6-mercaptopurine
ABC – ATP-binding cassette
ACTB – actin beta
ALL – acute lymphoblastic leukemia
DMEM – Dulbecco’s modified eagle medium
DMSO – dimethyl sulfoxide
D-PBS – Dulbecco’s phosphate buffered saline
DY – dipyridamole
ENBT1 – equilibrative nucleobase transporter 1
ENT1 – equilibrative nucleoside transporter 1
ENT2 – equilibrative nucleoside transporter 2
ENT4 – equilibrative nucleoside transporter 4
FBS – fetal bovine serum
G418 – geneticin
GAPDH - glyceraldehyde 3-phosphate dehydrogenase
GFP – green fluorescent protein
HEK293 – human embryonic kidney 293
HPRT - hypoxanthine-guanine phosphoribosyltransferase
HRP – horseradish peroxidase
IMDM – Iscove’s modified Dulbecco medium
MRP – multidrug resistance protein
MTT - (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)

NMG – N-methyl-D-glucamine

PBS – phosphate buffered saline

RNA18SN5 – 18S ribosomal N5

RPMI – Roswell Park Memorial Institute

SLC – solute carrier

TBS – tris-buffered saline

TPMT – thiopurine methyltransferase

e) Recommended section: Metabolism, Transport, and Pharmacogenomics
ABSTRACT

6-Mercaptopurine (6-MP) is used extensively in the treatment of acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases. Our lab determined previously, using a recombinant HEK293 cell model, that the SLC43A3-encoded equilibrative nucleobase transporter 1 (ENBT1) transports 6-MP into cells and significantly impacts the cytotoxicity of 6-MP in that model. To further investigate the clinical relevance of this finding, we now extend this work to an analysis of the impact of SLC43A3/ENBT1 expression and function on 6-MP uptake and cytotoxicity in leukemic lymphoblasts, the therapeutic target of 6-MP in ALL. A panel of ALL cell lines was assessed for SLC43A3/ENBT1 expression, ENBT1 function, and sensitivity to 6-MP. There was a significant difference in SLC43A3 expression among the cell lines that positively correlated with the rate of ENBT1-mediated 6-MP uptake. Cells with the lowest expression of SLC43A3 (SUP-B15: V_max - 22 ± 5 pmol/µl/s) were also significantly less sensitive to 6-MP induced cytotoxicity than were the highest expressing cells (ALL-1: V_max - 69 ± 10 pmol/µl/s). Furthermore, knockdown of ENBT1 using shRNAi in RS4;11 cells caused a significant decrease in ENBT1-mediated 6-MP uptake (V_max: RS4;11 - 40 ± 4 pmol/µl/s; RS4;11 shRNAi - 26 ± 3 pmol/µl/s) and 6-MP cytotoxicity (EC_{50}: RS4;11: 0.58 ± 0.05 µM; RS4;11 shRNAi: 1.44 ± 0.59 µM). This study showed that ENBT1 is a major contributor to 6-MP uptake in leukemia cell lines, and may prove to be a biomarker for the therapeutic efficacy of 6-MP in patients with ALL.

Keywords: 6-mercaptopurine, acute lymphoblastic leukemia, purine transporters, drug resistance, biomarkers
SIGNIFICANCE STATEMENT

This study shows that ENBT1 is responsible for the transport of 6-MP into leukemia cells and that its level of expression can impact the cytotoxicity of 6-MP. Further studies are warranted to investigate the therapeutic implications in patient populations.
INTRODUCTION

The nucleobase analogue, 6-mercaptopurine (6-MP), in combination with other drugs such as methotrexate, is a mainstay of maintenance protocols for the treatment of acute lymphoblastic leukemia (ALL) (Pui, Yang et al. 2015, Toft, Birgens et al. 2018), the most common malignancy in children and adolescents. While the survival rate of pediatric patients with ALL has increased in recent decades, there are still about 20% of patients who do not respond adequately to treatment and experience relapses with far lower survival rates (Chouchana, Fernandez-Ramos et al. 2015). A complicating factor in the use of 6-MP to treat ALL is the wide variability in its plasma concentration (Lonnerholm, Kreuger et al. 1986), as well as in the levels of active intracellular thionucleotide metabolites, achieved with a standard dose (Lennard 1992, Estlin 2001, Schmiegelow, Nielsen et al. 2014). This suggests extensive individual variability in factors that influence 6-MP metabolism and biodistribution. 6-MP must be metabolized by intracellular enzymes to its phosphorylated derivatives in the target cells to exert its cytotoxic effects. Changes in activity of intracellular enzymes such as thiopurine methyltransferase (TPMT) contribute to clinical variability in thioguanine nucleotide levels (Lennard, Cartwright et al. 2015, Abaji and Krajinovic 2017). However, TPMT polymorphisms do not explain all of the therapeutic variability observed, and particularly not the variable plasma concentrations (Chouchana, Fernandez-Ramos et al. 2015, Patel and Papachristos 2015); nor do changes in other genes/proteins that have been linked with variations in 6-MP activity such as PRPS1, NUDT15, mTORC1, MSH6, and NT5C2 (Tzoneva, Perez-Garcia et al. 2013, Li, Li et al. 2015, Liu, Janke et al. 2017, Tanaka 2017, Vo, Lee et al. 2017, Zgheib, Akika et al. 2017, Dieck, Tzoneva et al. 2018, Evensen, Madhusoodhan et al. 2018). Further understanding of factors that influence 6-MP activity is still required in order to optimize treatment protocols.

Hydrophilic drugs such as 6-MP require specific transporter proteins to enter and exit cells. Variations in transporter expression/activity are well known to impact both the clinical
effectiveness of drugs and their off-target toxicities (Nakanishi 2007, Colas, Ung et al. 2016, Wu and Li 2018). Since 6-MP produces its therapeutic effects via interference with intracellular processes, the very first step in 6-MP action, prior to conversion to its therapeutic cytotoxic form, is its transfer into leukemic cells across the plasma membrane. The ABC transporters MRP4 (ABCC4) and MRP5 (ABCC5) are known to mediate the efflux of 6-MP and metabolites from cells (Wijnholds, Mol et al. 2000, Wielinga, Reid et al. 2002, Janke, Mehralivand et al. 2008, Tanaka, Manabe et al. 2015, Liu, Janke et al. 2017). However, the mechanism by which 6-MP gets into cells, especially lymphoblasts (the target in ALL treatment), remained elusive until the recent identification of the SLC43A3-encoded equilibrative nucleobase transporter 1 (ENBT1). There are two alternative splice variants of SLC43A3 that we have shown to encode transport proteins that are functionally similar with respect to their ability to transport 6-MP and adenine (Ruel, Nguyen et al. 2019). Furthermore, we have established that ENBT1, heterologously expressed in HEK293 cells, can transport 6-MP at concentrations within the therapeutic range. We also showed using that model that changes in ENBT1 activity directly impact the ability of 6-MP to reduce cell viability. Given these findings, we now propose that endogenous ENBT1 expression may be an important variable in 6-MP accumulation by acute lymphoblastic leukemia cells, and that variations in ENBT1 activity may modify the therapeutic effectiveness of 6-MP. In the present study we show for the first time that acute lymphoblastic leukemia cells express SLC43A3 and exhibit robust ENBT1-mediated 6-MP transport activity. Furthermore, the rate of 6-MP accumulation by these cell lines correlates directly with the level of expression of SLC43A3.

MATERIALS AND METHODS

Materials: [8-14C]-6-MP (50–60 mCi/mmol), and [3H]-water (1 mCi/g) were obtained from Moravek Biochemicals (Brea, CA). Adenine, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dipyridamole (DY), geneticin (G418), Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin, D-glucose, doxycycline, 2-mercaptoethanol,
polybrene, and puromycin were purchased from Sigma-Aldrich (St. Louis, MO). Roswell Park Memorial Institute (RPMI) 1640 medium and the ECL prime western blotting system were purchased from Cytiva Life Sciences (Marlborough, MA). All primers were ordered through Integrated DNA Technologies (Coralville, IA). Agarose, oligo (dT)12–18 primer, Iscove’s Modified Dulbecco’s Media (IMDM), HEPES, sodium pyruvate, PowerUp SYBR Green, HALT protease inhibitor cocktail, TRIzol Reagent and SuperScript III Reverse Transcriptase came from Thermo Fisher Scientific (Waltham, MA). The 100 bp DNA Ladder was supplied by Truin Science (Edmonton, AB). Leu-Fect A was purchased from RJH Biosciences (Edmonton, AB). MOLT-4, NALM-6, SUP-B15, and HEK293 were purchased from ATCC (Manassas, VA). ALL-1, REH, and RS4;11 cells were generously provided by Dr. David Eisenstat (University of Alberta, Edmonton). The antibodies used for immunoblotting were mouse monoclonal IgG1 anti-Myc antibody (Clone 4A6, 05-724, Lot #3013479; EMD Millipore, Canada), rabbit polyclonal anti-SLC43A3 (HPA030551, Lot #000001575; Sigma-Aldrich, St. Louis, MO), and mouse monoclonal anti-β-actin (C4, sc-47778, Lot #B0719; Santa Cruz Biotechnology Inc., Texas, USA). Secondary antibodies were mouse anti-rabbit IgG-HRP (sc-2357, Lot #2517) and m-IgGk BP-HRP (sc-516102, Lot #F1016) from Santa Cruz Biotechnology. The characteristics of the cell lines used in this study are shown in Supplemental Table 1. SMARTvector 2.0 Inducible Lentiviral shRNA particles targeting SLC43A3 and SMARTvector 2.0 Non-Targeting shRNA Control particles were from GE Healthcare Dharmacon, Inc. (Lafayette, CO). SMARTvector 2.0 Lentiviral shRNA particles bind to cells and deliver their shRNA to the cytoplasm. The SMARTvector 2.0 includes a TurboGFP reporter gene to facilitate assessment and optimization of transduction efficiencies, and also contains a puromycin resistance gene for selection and isolation of clonal cell populations.

**Cell Culture:** ALL-1, MOLT-4, RS4;11, NALM-6, and REH cells were cultured in RPMI 1640 medium with 10% FBS supplemented with D-glucose (4500 mg/L), sodium pyruvate (1 mM),
penicillin (100 U/mL), streptomycin (100 µg/mL), and HEPES (10 mM). SUP-B15 cells were cultured in IMDM but with 20% FBS and 0.05 mM 2-mercaptoethanol. Suspended cells were centrifuged and washed in appropriate assay buffer solutions prior to their use in subsequent assays. HEK293 cells were cultured in DMEM with 10% FBS, penicillin (100 U/ml), streptomycin (100 µg/mL), and sodium pyruvate (1 mM). G418 was added (300 µg/ml) in the SLC43A3-HEK293 (HEK293 cells stably transfected with SLC43A3) cell media to maintain selection pressure on the stable transfectants. The HEK293 cells were removed from flasks by exposure to 0.05% trypsin/0.18 mM EDTA for 5 minutes at 37°C and the suspended cells were washed in the appropriate buffer solution (without G418) immediately prior to use in subsequent assays.

**Cell Viability:** Cells were seeded into a 24-well plate at a density of 5x10^4 cells/well in culture medium. Following plating, medium containing 6-MP (75 nM–1.28 mM) was added and incubated for 48 hours at 37°C in a humidified 5% CO2 atmosphere. Cells were then transferred to a 1.5 mL microcentrifuge tube and centrifuged at 3000 rcf for 10 min. Following centrifugation, media was removed and replaced with 250 µL of Dulbecco’s PBS (D-PBS; 137 mM NaCl, 2.7 mM KCl, 6.3 mM Na2HPO4, 1.5 mM KH2PO4, 0.5 mM MgCl2, 0.9 mM CaCl2, pH 7.4) containing MTT (1 mg/ml) for 90 minutes. Microcentrifuge tubes were centrifuged again at 23,500 rcf for 15 min and the D-PBS containing MTT solution was removed. The resultant formazan crystals were solubilized in 450 µl of DMSO and absorbance was measured at 570 nm in a Bio-Rad xMark Microplate Absorbance Spectrophotometer (Hercules, CA).

**Nucleobase Uptake:** Cells were suspended in nominally sodium-free buffer (to eliminate potential contribution of sodium-dependent transporters) (N-methyl-D-glucamine (NMG) buffer; 140 mM NMG, 5 mM KCl, 4.2 mM KHCO3, 0.36 mM K2HPO4, 0.44 mM KH2PO4, 10 mM HEPES, 0.5 mM MgCl2, 1.3 mM CaCl2, pH 7.4) containing 1 µM DY (to block potential equilibrative nucleoside transporter (ENT)-mediated uptake) and incubated for 15 minutes at room temperature prior to assay. Cellular uptake was initiated by adding 250 µl cell suspension
to 250 µl [14C]6-MP layered over 21:4 silicone:mineral oil (v:v) (200 µl) in 1.5 ml microcentrifuge tubes. The uptake reaction was terminated after specified times by centrifugation of the cells through the oil layer at ∼10,000g. The aqueous layer was aspirated and the tube was washed with ∼1 ml of NMG buffer prior to removal of the oil layer. The resulting cell pellet was digested in 1 M NaOH overnight (∼16 hours), with aliquots of digested cells assessed for radioactive content using standard liquid scintillation counting techniques in a Beckman Coulter LS6500 scintillation system (Brea, CA). Total uptake was defined as the uptake of [14C]6-MP in the absence of adenine. Non-mediated uptake was defined as the uptake of [14C]6-MP by cells in the presence of 1 mM adenine. Mediated uptake was defined as the difference between the total and non-mediated uptake components. Cell volume (in microliters) was estimated by incubating cells with [3H] water for 3 minutes, centrifuging the cells through the oil layer, sampling 100 µl of the supernatant, and then processing as described above. Total cellular water volume was determined from the ratio of the decays per minute of the cell pellet to the decays per minute of the supernatant, allowing for interexperimental normalization via calculation of picomoles of substrate accumulated per microliter of cell-associated water.

**Polymerase Chain Reaction:** Cells from confluent 10-cm plates were suspended in 1 ml of TRIzol reagent and homogenized for extraction of RNA according to the manufacturer’s protocol (Thermo Fisher Scientific). Total RNA concentration and purity were determined using a Nanodrop 2000 spectrophotometer (Life Technologies Inc.). For qualitative polymerase chain reaction (PCR), 1 µg of total RNA was reverse transcribed to cDNA using Oligo (dT)12–18 primer and SuperScript III Reverse Transcriptase, and amplified using recombinant Taq DNA Polymerase (Thermo Fisher Scientific), and primers designed flanking the nucleotide sequence of the 13 additional amino acids in SLC43A3_2 (forward primer: 5’- CTGTGTGGACCAGATGC; reverse primer 3’- TAGCCCTCACCTCTTGCA), or a primer designed within the nucleotide sequence for the 13 additional amino acids in SLC43A3_2 (forward primer: 5’-
GAGACCTTTTTTCTACTCC) The following conditions were used for amplification: 3 minutes at 95°C, followed by 40 cycles of 30 seconds at 95°C; 30 seconds at 56°C; and 60 seconds at 72°C, followed by extension for 10 minutes at 72°C in a BioRad T-100 Thermocycler.

Semiquantitative PCR was conducted using cDNA (~100 ng/well) prepared as described above with the primer sets shown in Supplemental Table 2 using Power Up SYBR Green fluorescence on a Roche Light Cycler 480 System (Cardiovascular Research Centre, Edmonton, Canada). Primer efficiency and melt curves were assessed prior to their use for gene expression analysis. Semiquantitative PCR conditions were: 2 minutes at 50°C (UDG activation); 2 minutes at 95°C (denaturation), followed by 50 cycles of 15 seconds at 95°C; and 60 seconds at 60°C for amplification, with a final melt curve analysis. Gene expression was normalized to either glyceraldehyde-3-phosphate dehydrogenase (GAPDH) alone or the geographic mean of three separate reference genes: GAPDH, 18S ribosomal N5 (RNA18SN5), and β-actin (ACTB), and analyzed relative to expression in the untransfected HEK293 or ALL-1 cells using the ΔΔCt method.

Immunoblotting: Samples were extracted using RIPA buffer (150 mM NaCl, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate, 1% SDS) containing HALT protease inhibitor cocktail and adjusted to 2% (v/v) β-mercaptoethanol. Samples were resolved using SDS-PAGE on 12.5% (w/v) acrylamide gels and transferred to Immobilon-P PVDF membranes at 280mA for 1.5 hours. Following the transfer, membranes were rinsed in Tris buffered saline (TBS; 0.15 M NaCl, 50 mM Tris, pH 7.5) and incubated with TBS-TM (TBS containing 0.2% v/v Tween-20 and 5% w/v skim milk powder) at room temperature for 1 hour to block nonspecific binding. Anti-Myc, rabbit anti-SLC43A3, or mouse anti-β-actin at 1:1000, 1:250 and 1:500, respectively, were then incubated for 16 hours at 4°C in TBS-TM (containing 1% skim milk). Membranes were washed several times in TBS-TM before being incubated in mouse anti-rabbit IgG-HRP or m-IgGk BP-HRP at 1:5000 or 1:3000, respectively, for 1 hour at room temperature. After further
washing in TBS-T (TBS containing 0.2% (v/v) Tween-20), proteins were detected using ECL prime western blotting system and visualized on an Amersham Imager 680 (GE Healthcare, Chicago, IL). Image J software was used to conduct the densitometry analyses.

**Suppression of SLC43A3 by shRNAi**

**HEK293 cells** – The base HEK293 cells and SLC43A3-HEK293 cells were transduced with the SMARTvector Inducible Lentiviral shRNA vector containing SLC43A3 shRNAi according to the manufacturer's protocol and stably selected using puromycin. To induce expression of the shRNA, doxycycline was added to the cells at 400 ng/mL for 48 or 72 hours before analysis. shRNA expression efficiency was assessed based on the reporter Green Fluorescent Protein (GFP) fluorescence. SLC43A3-knockdown was confirmed by immunoblots with anti-SLC43A3 antibodies.

**Leukemia cells** – Attempts to transduce ALL-1 and RS4;11 leukemia cells with the SMARTvector Inducible Lentiviral shRNA system using the same procedure that was used for the HEK293 cells were unsuccessful. Therefore, transfection of RS4;11 cells with SLC43A3 shRNAi vector lentiviral particles or non-targeting control shRNAi was done using Leu-Fect A according to manufacturer’s protocols. Cells were transfected and incubated at 37°C in a humidified 5% CO₂ atmosphere for 48 hours in culture media without FBS or penicillin/streptomycin containing the Leu-Fect A and the shRNAi lentiviral particles. Following the 48 hours, culture media containing FBS and penicillin/streptomycin was added and cells were grown for 1 week. Puromycin was then added at 2 µg/mL and the cells were incubated until no untransfected cells (cultured in parallel) remained. Transfected cells were allowed to continue proliferating in the presence of 1 µg/mL puromycin to a density of approximately 1,000,000 cells/mL. Cells were then sorted on a BD FACSARia III BSL2 cell sorter (BD...
Biosciences, San Jose, CA) (University of Alberta, Faculty of Medicine & Dentistry Flow Cytometry Facility) for GFP positive cells and maintained in culture media with 1 µg/mL puromycin. GFP expression was assessed on each cell passage using a Zeiss inverted widefield epifluorescence Axio Observer Z1 microscope (Oberkochen, Germany) at 388 nm, and cells were re-sorted if expression started to decrease (this was typically done every 5 passages to ensure sufficient signal and knockdown of our target).

**Data Analysis and Statistics:** Data are expressed as mean ± S.D from a minimum of five independent experiments done in technical duplicate or triplicate. A sample size of 5 is the minimum needed to define statistical differences based on the known variability inherent in substrate flux studies. Higher sample sizes (N>10) were used for the more variable types of assays such as the immunoblot densitometry measurements. Nonlinear curves were fitted to the transport and cytotoxicity data, and statistical analyses were done using GraphPad Prism 8.01 software. In all cases, if the P value determined from a statistical test was less than 0.05, the difference was considered significant and the null hypothesis (no difference between data sets) was rejected. Cytotoxicity curves were best represented by a biphasic curve fit (vs. one phase). Correlation data was fit using linear regression and statistically tested using the Spearman rank correlation coefficient. Influx data was fit using a one phase association for time course data and Michaelis-Menten curves were fit to the concentration dependent uptake data for determination of $K_m$ and $V_{max}$ values. Statistical differences between $K_m$ and $V_{max}$ values were determined using the extra sum-of-squares F test. Significant differences between groups were assessed using a 1-way or 2-way ANOVA, corrected for multiple comparisons with the Holm-Sidak method.
RESULTS

SLC43A3 expression: All of the cell lines tested expressed both isoforms of SLC43A3, with isoform 1 being dominant in all cases (Figure 1A & B). Immunoreactivity using an ENBT1-selective antibody was also detected at the molecular mass expected (~54kDa) for the ENBT1 protein in all cell lines (Figure 1C). Most of the cell lines had similar levels of expression of SLC43A3 transcript and ENBT1 protein (Table 1), with the exception of NALM-6 and SUP-B15 which had about a 2-fold lower expression relative to the other cell lines tested.

Expression of other transporters/enzymes: The expression of transcripts encoding enzymes involved in 6-MP metabolism (HPRT, TPMT) and other transporters (i.e., ABCC4, ABCC5, SLC29A1, SLC29A2, SLC29A4) that have been implicated in nucleoside/nucleobase flux are shown in Figure 2. Of all the genes tested, only SLC29A4, which encodes for equilibrative nucleoside transporter 4 (ENT4), varied significantly among the cell lines with the SUP-B15 cells having a 4-fold higher expression than the ALL-1 cells and NALM-6 cells having ~50-fold lower expression than the ALL-1 cells.

6-MP uptake: Initial studies were done to assess the rate of uptake of 6-MP by the ALL-1 and SUP-B15 cell lines using either 1 µM (which reflects its therapeutic plasma concentration (Lonnerholm, Kreuger et al. 1986)) or 100 µM 6-MP. [14C]6-MP uptake was very rapid with a $t_{1/2}$ of ENBT1-mediated uptake (adenine inhibitable) of ~4.0 sec and ~2.3 sec at 1 µM and 100 µM, respectively for the ALL-1 cells, and ~1.6 sec and ~3.5 sec, respectively, for the SUP-B15 cells (Figure 3). Based on these time-course profiles, a 2 sec timepoint was chosen to estimate initial rate of influx; this is the shortest incubation time that can be practically achieved using this method. When initial rates were derived in this manner over a range of [14C]6-MP concentrations, a classic Michaelis-Menten relationship was observed with a $V_{max}$ of 69 ± 10 pmol/µl/s and a $K_m$ of 141 ± 40 µM for ALL-1 cells. In the SUP-B15 cells, we observed a significantly lower $V_{max}$ for ENBT1-mediated 6-MP uptake of 22 ± 5 pmol/µl/s and a $K_m$ of 133 ±
53 µM (Figure 3E). These $K_m$ values for 6-MP transport by ENBT1 are similar to those determined previously for $SLC43A3$-transfected HEK293 cells (Ruel, Nguyen et al. 2019).

Several other leukemia cell lines (RS4:11, REH, NALM-6, MOLT-4) were also examined for their adenine-inhibitable (ENBT1-mediated) uptake of $[^{14}C]$6-MP revealing a similar affinity across cell lines. They did, however, vary significantly in the $V_{max}$ of 6-MP transport; these data are summarized in Table 1.

**6-MP cytotoxicity:** Each of the cell lines tested displayed a biphasic sensitivity to 6-MP with ~45% of the cells sensitive to 6-MP with an $EC_{50}$ of ~1 µM (sensitive cell component) and the remainder requiring concentrations greater than 500 µM to affect cell viability (resistant cell component) (Figure 4). Given that the therapeutic concentrations of 6-MP are in the range of 1 µM, cell lines were compared with respect to the $EC_{50}$ of 6-MP cytotoxicity for the sensitive component. ALL-1 cells were the most sensitive to 6-MP ($EC_{50} = 0.66 \pm 0.23$ µM) and the SUP-B15 cells were the least sensitive ($EC_{50} = 2.06 \pm 0.49$ µM). Cytotoxicity data for all cell lines is compiled in Table 1.

**Correlation of 6-MP uptake, cytotoxicity, and gene expression:** All of the independent measures made in this study were compared to reveal any significant correlations. This analysis led to only two significant correlations. The rate of 6-MP uptake ($V_{max}$) positively correlated with $SLC43A3$ mRNA expression (Spearman $r = 0.89$) (Figure 5A). However, there was no significant correlation between 6-MP uptake ($V_{max}$) and the cytotoxicity of 6-MP in the ‘sensitive’ cell populations (1st phase of the cytotoxicity profiles) (Spearman $r = 0.03$) when comparing the full panel of cell lines. Unexpectedly, there was a significant positive correlation between the first phase cytotoxicity $EC_{50}$ value and the expression of $SLC29A4$ (Spearman $r = 0.89$) (Figure 5B). In other words, as $SLC29A4$ expression increased, the cytotoxicity of 6-MP decreased.

**6-MP resistant cells:** To further examine the 6-MP-resistant cell population that was apparent from the cytotoxicity profiles shown in Figure 4, ALL-1 cells were grown in the presence of 640 µM (Figure 3E).
µM 6-MP for 48 hr (concentration selected to ensure complete elimination of the 6-MP-sensitive cell population; see Figure 4A), and then sub-cultured for at least 10 passages. These cells retained their relative insensitivity to 6-MP. The resistant ALL-1 cells (ALL-1R) still showed a biphasic cytotoxicity profile to 6-MP (Figure 6A), but with only ~20% of the cell population being relatively sensitive to 6-MP induced cell death (EC$_{50}$ = 1.41 ± 0.63 µM; not significantly different than that obtained for the parent ALL-1 cell line). However, these ALL-1R cells had a reduced rate of uptake of 6-MP (determined using the ~K$_{m}$ concentration of 100 µM) relative to the parent cell line (Figure 6B). In terms of gene expression, the ALL-1R cells had reduced expression of TPMT and SLC43A3, and an increased expression of SLC29A4 and ABCC5 (Figure 6C). Immunoblotting confirmed a decrease in ENBT1 protein expression in ALL-1R cells when normalized to β-actin levels (Figure 6D).

**shRNAi suppression of SLC43A3:** The initial shRNAi suppression studies were done using the SLC43A3-HEK293 cells that we created and reported on previously (Ruel, Nguyen et al. 2019). SLC43A3-HEK293 cells were stably transduced with a lentiviral vector containing SLC43A3-targeting shRNAi under the control of a doxycycline-sensitive promoter (Figure 7A). Immunoblotting and PCR indicated that SLC43A3 transcript was suppressed upon incubation of these cells with doxycycline for 72 hours (Figure 7B, C) with an ~5-fold reduction in expression observed. This is corroborated by the uptake data which showed a 5-fold reduction in the rate of 6-MP uptake upon treatment with doxycycline to induce the shRNAi expression (K: - Dox: 0.77 ± 0.08 sec$^{-1}$; + Dox: 0.14 ± 0.02 sec$^{-1}$ (Figure 7D). Furthermore, upon activation of the shRNAi expression, the SLC43A3-HEK293 cells were significantly less sensitive to 6-MP induced cytotoxicity (EC$_{50}$: - Dox = 0.54 ± 0.05 µM; + Dox = 1.58 ± 0.07 µM) (Figure 7E). Interestingly, exposure of the un-transfected base HEK293 cells to doxycycline for 72 hours actually enhanced their sensitivity to 6-MP (Figure 7E). This finding indicates that the decrease in 6-MP
sensitivity upon activation of the \textit{SLC43A3}\textsuperscript{-}shRNAi expression was due to the knockdown of \textit{SLC43A3} and not a non-specific effect of the doxycycline exposure.

For reasons that remain obscure, this same inducible knockdown approach was not successful in the leukemia cell lines. Therefore, we transiently transfected the RS4;11 cell line with the shRNAi containing vectors (\textit{SLC43A3} targeting and control) as described in Methods. This resulted in robust expression of the shRNAi, based on GFP reporter levels, as well as a significant reduction in ENBT1 immunoreactivity, even in the absence of doxycycline (Figure 8A). Cells transfected with the \textit{SLC43A3} shRNAi containing vector displayed a 35% reduction in ENBT1-mediated 6-MP uptake (V\textsubscript{max}: RS4;11 - 40 \pm 4 pmol/µl/s; RS4;11 shRNAi - 26 \pm 3 pmol/µl/s) (Figure 8B). The \textit{SLC43A3} shRNAi expressing cells were also significantly less sensitive to the cytotoxic effects of 6-MP (EC\textsubscript{50}: RS4;11: 0.58 \pm 0.05 µM; RS4;11 shRNAi: 1.44 \pm 0.59 µM) (Figure 8C). Gene expression analysis showed a significant paradoxical (in spite of the decrease in ENBT1 protein and function) 2-fold increase in \textit{SLC43A3} transcript and also a 4-fold increase in \textit{SLC29A2} (ENT2) transcript (Figure 8D).

**DISCUSSION**

This study clearly shows that \textit{SLC43A3} is highly expressed in acute lymphoblastic leukemia cell lines, and that it mediates the uptake of 6-MP by these cells. This is consistent with the relatively high expression of \textit{SLC43A3} in bone marrow and lymphoid tissues as reported by the Human Protein Atlas (proteinatlas.org) (Uhlen, Fagerberg et al. 2015). There is a strong correlation between the expression of \textit{SLC43A3} and the rate of 6-MP uptake among these cell lines (Figure 5A). This suggests that the protein encoded by \textit{SLC43A3} is a major player in the cellular accumulation of 6-MP by leukemic lymphoblasts. While 6-MP uptake correlated with the expression of \textit{SLC43A3}, this did not translate to a correlation with 6-MP-mediated cytotoxicity in the cell panel studied. This suggests that relatively small changes (~2-fold in this case) in \textit{SLC43A3}/ENBT1 activity may not be sufficient to be a factor in 6-MP cytotoxicity. The difference
in 6-MP cytotoxicity among cell lines was likely more dependent on differences in the activity of intracellular metabolic enzymes such as TPMT. Nevertheless, larger changes in SLC43A3 expression may be clinically relevant. Over 1600 coding sequence variants (non-synonymous SNPs) and 26 splice variants have been identified to date for SLC43A3 (Cunningham, Allen et al. 2022). Many of these are predicted to affect protein function (Poly-Phen score >0.9) (Adzhubei, Schmidt et al. 2010). However, none have been characterized, and there is limited information on allele frequency in human populations.

We showed in a previous study that there was a significant enhancement of 6-MP cytotoxicity when SLC43A3 was recombinantly expressed in an HEK293 cell model, which normally has low endogenous levels of SLC43A3 (Ruel, Nguyen et al. 2019). We also showed, in the present study, that knockdown of SLC43A3 via transfection of these SLC43A3-HEK293 cells with shRNAi targeting SLC43A3 led to a dramatic reduction in 6-MP uptake and cytotoxicity (Figure 7). A similar result was obtained when RS4;11 leukemia cells were transfected with this same SLC43A3 shRNAi expression vector. The SLC43A3 shRNAi transfected RS4;11 cells showed a dramatic decrease in the rate of ENBT1-mediated 6-MP uptake, the amount of ENBT1 protein, as well as a significant decrease in their sensitivity to the cytotoxic activity of 6-MP, relative to cells transfected with the non-targeting control shRNAi (Figure 8). However, in the RS4;11 cells the shRNAi was expressed, based on the GFP reporter, even in the absence of doxycycline. This may reflect the higher level of the construct internalized in the RS4;11 cells (likely due to the inclusion of Leu-Fect-A in the transfection media). Therefore, SLC43A3-encoded ENBT1 is clearly a major contributor to the uptake of 6-MP and its cytotoxicity in the RS4;11 cell line. The paradoxical increase in SLC43A3 expression levels observed in the SLC43A3 shRNA transfected RS4;11 cells may be due to an effect of the high level of expression of the shRNAi in this model which can result in a compensatory increase in the target mRNA with the shRNAi suppressing mRNA translation (Neumeier and Meister 2020). There was also a significant
increase in the expression of SLC29A2. This gene encodes for ENT2 which can transport nucleobases with low affinity. So, this may be a compensatory response in these cells to the loss of the primary purine nucleobase transporter ENBT1.

To examine the potential contribution of SLC43A3 downregulation to the development of cellular resistance to 6-MP, we selected a 6-MP resistant subclone (ALL-1R) from the ALL-1 cells by incubation with 640 µM 6-MP for 48 hours. The resistant cell line showed a modest reduction in the expression of SLC43A3 as well as a reduced rate of uptake of 6-MP (Figure 6). However, the ALL-1R cells also had a reduced expression of TPMT, which would contribute to a reduced cellular accumulation of 6-MP metabolites, and an upregulation of the efflux pump ABCC5 (MRP5). These combined changes, and likely further metabolic alterations not assessed in this study led, to the observed profound level of resistance of the ALL-1R cells to 6-MP. The 6-MP resistant cells also had a dramatic upregulation of SLC29A4 (Figure 6C). This finding is congruent with our correlation data that shows a strong negative association between SLC29A4 expression and the cytotoxicity of 6-MP in the cell lines examined (Figure 5B). SLC29A4 encodes for ENT4, an acidic pH-activated adenosine and monoamine transporter (Barnes, Dobrzynski et al. 2006, Tandio, Vilas et al. 2019). ENT4 does not transport nucleobases, and the role of ENT4 in lymphoblasts has not been investigated. While there is no known direct link between 6-MP and ENT4, it has been noted in the literature that 5-HT2A receptor stimulation and/or serotonin uptake have been attributed to the activation of Rac1 in certain conditions (Dai, Dudek et al. 2008, Saponara, Visentin et al. 2018). Rac1 is known to be inhibited by 6-MP. Therefore, one may speculate that SLC29A4 upregulation could be a novel resistance mechanism, and further investigation is clearly warranted.

In summary, our study shows that SLC43A3-encoded ENBT1 is highly expressed in acute lymphoblastic leukemia cells and is the predominant mechanism for 6-MP accumulation by
these cells. While minor differences in SLC43A3/ENBT1 expression do not appear to affect 6-MP cytotoxicity, major changes in the expression of SLC43A3 due to, for example, gain or loss of function polymorphisms, may have a significant impact on 6-MP therapeutic efficacy in ALL and other clinical indications.
ACKNOWLEDGEMENTS

Experiments were performed at the University of Alberta, Faculty of Medicine & Dentistry Flow Cytometry Facility, which receives financial support from the Faculty of Medicine & Dentistry and Canada Foundation for Innovation (CFI) awards to contributing investigators.

Ruel, N.M. recognizes the support and funding from the Rachel Mandel Lymphoma and Blood Cancers Research Fund for his graduate thesis work.

We wish to acknowledge the valuable input of Dr David Eisenstat (Oncology, University of Alberta) to this project. As a member of the supervisory committee for Nicholas Ruel, the first author on this manuscript, he not only provided cell lines, but also important advice regarding interpretation of the results obtained.

We also wish to acknowledge the critical technical support for this project provided by laboratory technician Deborah L Sosnowski.

AUTHORSHIP CONTRIBUTIONS

Participated in research design: Hammond, Nguyen, and Ruel
Conducted experiments: Ruel, Nguyen, Kim, and Andrade
Contributed new reagents or analytic tools: N/A
Performed data analysis: Hammond, Nguyen, and Ruel
Wrote or contributed to the writing of the manuscript: Hammond, and Ruel
REFERENCES


FOOTNOTES

This work was supported by funding provided to JRH by the Canadian Institutes of Health Research under Grant #168913.

No author has an actual or perceived conflict of interest with the contents of this article.
FIGURE LEGENDS

Figure 1: SLC43A3 isoform expression and ENBT1 protein levels: cDNA was prepared from mRNA isolated from ALL-1, MOLT-4, REH, RS4;11, NALM-6, and SUP-B15 human acute lymphoblastic leukemia cell lines. Qualitative PCR was used to screen for the two known isoforms of SLC43A3 (SLC43A3_1 and SLC43A3_2) using primers that flanked the region that differs between the two isoforms (to amplify both isoforms; Panel A) and a primer set where the forward primer was designed against the region that is unique to SLC43A3_2 (to specifically amplify isoform 2; Panel B) (See Supplementary Table 2 for primer sequences). Panel C shows a representative immunoblot for ENBT1 in these cell lines. Samples were resolved on SDS-PAGE gels, transferred to polyvinyl membranes and probed with anti-ENTB1 (upper) and anti-β-actin (lower) antibodies. ‘L’ indicates the respective DNA (Panel A and B) and protein (Panel C) molecular size ladders.

Figure 2: Transcript levels of various enzymes and transporters potentially associated with 6-MP metabolism. Gene expression was assessed by semi-quantitative PCR and is shown relative to the ALL-1 cell line. Expression was normalized to 3 separate reference genes (GAPDH, RNA18SN5, and ACTB) and quantified using the delta-delta Ct method. (A-H) Relative expression of SLC43A3, TPMT, SLC29A1, SLC29A2, SLC29A4, HPRT1, ABCC4, and ABCC5 as compared to ALL-1 cell line. Lines represent the mean ± SD of 6 independent samples done in triplicate.

Figure 3: [14C]6-MP transport by ENBT1. ALL-1 and SUP-B15 cells were incubated at room temperature with 1 µM (A, B) and 100 µM (C, D) [14C]6-MP for the indicated times (abscissa) in the absence (Total uptake) and presence (Non-mediated uptake) of 1 mM adenine. Transport was terminated by centrifugation of the cells through an oil layer. Cell pellets were digested.
overnight in 1 M NaOH and assessed their [\(^{14}\)C] content via liquid scintillation counting. ENBT1-mediated uptake is defined as the difference between the total uptake and the non-mediated uptake. Data are represented as the mean ± SD of 5 experiments done in duplicate. (E) The kinetics of ENBT1-mediated transport of 6-MP in ALL-1 and SUP-B15 cells were determined by incubating the cells in a range of concentrations of [\(^{14}\)C]6-MP for 2 seconds (ALL-1) or 3 seconds (SUP-B15) in the presence and absence of 1 mM adenine with ENBT1-mediated transport calculated as the adenine sensitive transport component. Data are shown as the pmol of 6-MP accumulated by the cells/µl of cell volume/second. Data points are the mean ± SD of 5 experiments done in duplicate.

**Figure 4: Cytotoxicity of 6-MP.** The leukemia cell lines indicated in panels A-F were plated at a density of 5x10^4 cells/well in 24-well plates and incubated with a range of concentrations of 6-MP for 48 hours at 37°C in a humidified incubator (5% CO\(_2\)/95% air). Cell viability was assessed using the MTT assay, and expressed as a percentage of the cell viability measured at 48 hours in the absence of 6-MP. Data were fitted with a biphasic concentration-response curve and each point represents the mean ± SD from the number of experiments (n) indicated on each panel.

**Figure 5: Correlation analyses.** Correlation of the various independent variables measured in this study revealed two significant (P<0.05) correlations among the cell lines between: (A) SLC43A3 expression and the rate (\(V_{\text{max}}\)) of ENBT1-mediated 6-MP uptake, and (B) the log EC\(_{50}\) for phase 1 (6-MP sensitive component) of the 6-MP cytotoxicity profile and the expression of SLC29A4. Data points represent the mean ± SD for each independent measure. Data was analyzed using simple linear regression and correlations assessed using the Spearman rank-order correlation method.
Figure 6: ALL-1 cells resistant to 6-MP have decreased SLC43A3 expression. 6-MP resistant ALL-1 cells (ALL-1R) were derived by incubating the cells with 640 µM 6-MP for 48 hours and sub-culturing the surviving cells for 10 passages. (A) Cells were assessed for their viability via the MTT assay after exposure to a range of concentrations of 6-MP as described in Figure 4. Data points are expressed as the mean ± SD of 6 (ALL-1) and 5 (ALL-1R) experiments and fitted to a biphasic concentration-response relationship. * Indicates a significant difference between the ALL-1R and ALL-1 cells using a 2-way ANOVA with a Holm-Sidak post hoc test (P<0.0001 for all points). (B) The rate of 6-MP accumulation by the ALL-1 and ALL-1R cells was determined as described in Figure 3. Bars represent the mean ± SD of 8 experiments. * Indicates a significant difference in the rate of influx (Student’s t-test, P=0.049). (C) Transcripts levels were determined as described in Figure 2 with the exception that GAPDH alone was used as the reference gene. Bars represent the mean ± SD of 5 - 7 independent samples done in triplicate. * Indicates a significant difference in gene expression between the ALL-1 and ALL-1R cells based on an unpaired t-test (P=0.032, 0.019, <0.0001, 0.0037 for TPMT, SLC43A3, SLC29A4, and ABCC5, respectively). (D) ENBT1 protein levels in ALL-1 and ALL-1R cell lines. Samples were resolved on SDS-PAGE gels, transferred to polyvinyl membranes and probed with anti-ENBT1 (upper) and anti-β-actin (lower) antibodies. The ratio of ENBT1 to β-actin determined by densitometry is indicated for each lane below the ENBT1 gel image.

Figure 7: shRNAi suppression of SLC43A3 decreases uptake and cytotoxicity of 6-MP in SLC43A3-transfected HEK293 cells. Myc-tagged-SLC43A3-HEK293 cells stably transfected with an inducible shRNAi vector targeting SLC43A3 were treated with or without 400 ng/µL doxycycline for 48 or 72 hours to induce shRNAi expression (with concomitant GFP). (A)
Expression of the GFP indicator without and with 72-hour exposure to doxycycline. Scale bars represent 100 microns. (B) MYC-ENBT1 levels before and after exposure to doxycycline for 72 hours. Samples were resolved on SDS-PAGE gels, transferred to polyvinyl membranes and probed with anti-MYC (upper) and anti-β-actin (lower) antibodies. (C) SLC43A3 transcript levels were quantified by semi-quantitative PCR using GAPDH as the reference gene in shRNAi-transfected SLC43A3-HEK293 cells following incubation with and without doxycycline for 48 and 72 hours. Expression levels in the base SLC43A3-HEK293 cells are shown for comparison. -Bars represent the mean ± SD of 4 - 6 independent samples done in triplicate. * Indicates a significant difference using a 1-way ANOVA with a Holm-Sidak post hoc test (P=0.0027). (D) Time course of the cellular uptake of 30 µM $[^{14}C]6$-MP by SLC43A3-targeting shRNAi transfected SLC43A3-HEK293 cells with and without exposure to doxycycline for 72 hours. Data are expressed as the mean ± SD of 5 experiments done in duplicate. * Indicates a significant difference ± doxycycline (multiple t-Test with a Holm-Sidak post hoc test, P=0.00016, 0.00011, <0.0001, <0.0001 for 2, 4, 6, and 8 second timepoints, respectively). (E) Effect of 6-MP on cell viability for HEK293 cells, HEK293 cells stably transfected with SLC43A3 (SLC43A3-HEK293) and SLC43A3-HEK293 cells stably transfected with SLC43A3-targeting shRNAi, with and without incubation of cells with doxycycline for 72 hours. Points represent the mean ± SD of 5 – 7 independent experiments. * Indicates a significant different ± doxycycline (2-way ANOVA with a Holm-Sidak post hoc test, P=<0.0001, <0.0001, 0.0005, 0.0281 for -5.9, -6.2, -6.5, and -6.8 (log molar 6-MP), respectively).

Figure 8: shRNAi knockdown of SLC43A3 in RS4;11 leukemia cells decreases both ENBT1-mediated uptake of 6-MP and 6-MP cytotoxicity. (A) ENBT1 protein expression in non-targeting shRNAi transfected (Control) and SLC43A3-targeting shRNAi (SLC43A3-shRNAi) transfected RS4;11 cells. Cell membrane samples from two independent experiments were resolved on SDS-PAGE gels, transferred to polyvinyl membranes and probed with anti-ENBT1
(upper) and anti-β-actin (lower) antibodies. **(B)** Kinetic analysis of [14C]6-MP uptake by RS4;11 cells transfected with non-targeting shRNAi (Control) or with SLC43A3-targeted shRNAi was conducted as described in **Figure 3.** Points represent the mean ± SD of 6 - 10 experiments done in duplicate. * Indicates a significant effect ± shRNAi (2-way Anova with a Holm-Sidak post hoc test, P=0.021, 0.021, 0.0003, <0.0001, <0.0001, 0.0174 for 60, 100, 120, 180, 240, and 300 µM 6-MP, respectively). **(C)** Cytotoxicity of 6-MP in RS4;11 cells transfected with non-targeting shRNAi (Control) or SLC43A3-targeting shRNAi. Assays were conducted as described for Figure 4. Points represent the mean ± SD of 6 – 9 experiments. * Indicates a significant effect of SLC43A3 knockdown (2-way Anova with a Holm-Sidak post hoc test, P=0.039, 0.028, <0.0001 for -5.3, -5.6, and -5.9 (log molar 6-MP), respectively). **(D)** Gene expression profiles of enzymes and transporters associated with 6-MP metabolism in RS4;11 cells transfected with non-targeting shRNAi (Control) or with SLC43A3-targeted shRNAi. Bars represent the mean ± SD of 5 – 6 independent samples done in triplicate. * Indicates a significant effect of shRNAi suppression of SLC43A3 (unpaired t-Test, P<0.05).
### TABLES

Table 1: Summary of experimental parameters measured

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>SLC43A3 transcript b</th>
<th>ENBT1 protein c</th>
<th>ENBT1-mediated transport</th>
<th>6-MP cytotoxicity d</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>$V_{\text{max}}$ (pmol/µL/sec)</td>
<td>% Sensitive</td>
</tr>
<tr>
<td>MOLT-4</td>
<td>1.10 ± 0.11 (7)</td>
<td>0.84 ± 0.34 (13)</td>
<td>87 ± 4 (5)</td>
<td>46 ± 14 (7)</td>
</tr>
<tr>
<td>ALL-1</td>
<td>1.01 ± 0.12 (7)</td>
<td>0.74 ± 0.38 (13)</td>
<td>69 ± 10 (5)</td>
<td>44 ± 10 (14)</td>
</tr>
<tr>
<td>RS4;11</td>
<td>1.00 ± 0.08 (7)</td>
<td>0.91 ± 0.42 (13)</td>
<td>52 ± 8 (5)</td>
<td>39 ± 8 (6)</td>
</tr>
<tr>
<td>REH</td>
<td>0.86 ± 0.07 (7)</td>
<td>1.07 ± 0.47 (13)</td>
<td>65 ± 2 (5)</td>
<td>28 ± 12 (6)</td>
</tr>
<tr>
<td>NALM-6</td>
<td>0.55 ± 0.06 (7)</td>
<td>0.48 ± 0.24 (6)</td>
<td>15 ± 2 (5)</td>
<td>37 ± 7 (9)</td>
</tr>
<tr>
<td>SUP-B15</td>
<td>0.53 ± 0.10 (7)</td>
<td>0.65 ± 0.37 (12)</td>
<td>22 ± 5 (5)</td>
<td>44 ± 12 (5)</td>
</tr>
</tbody>
</table>

a Mean ± SD from the number of independent experiments shown in parentheses

b Expression relative to ALL-1 (see Figure 2)

c Expression relative to β-actin (see Figure 1C for representative immunoblot)

d Data derived from the biphasic 6-MP cytotoxicity profiles shown in Figure 4. % Sensitive refers to the proportion of cells that were sensitive to low µM concentrations of 6-MP. EC$_{50}_1$ and EC$_{50}_2$ refer to the log molar concentrations of 6-MP that reduced the viability of the 6-MP sensitive and resistant cell populations, respectively.
Figure 4

A. ALL-1

B. MOLT-4

C. RS4;11

D. REH

E. NALM-6

F. SUP-B15
Figure 5

A

Spearman $r = 0.89^*$

Rate of $[^{14}C]6$-MP Transport $V_{max}$ (pmol/$\mu$L/sec)

Relative $SLC43A3$ Expression

B

Spearman $r = 0.89^*$

Relative $SLC29A4$ Expression

Log $EC_{50}$ (M)
Figure 7

A

- Dox
+ Dox

B

\(\alpha\)-MYC

- Dox (72 hr)  + Dox (72 hr)

\(\alpha\)-\(\beta\)-actin

- Dox (72 hr)  + Dox (72 hr)

C

Relative RNA Expression (Fold of HEK293)

SLC43A3-HEK293 cells
+shRNAi (- Dox, 48 hrs)
+shRNAi (+ Dox, 48 hrs)
+shRNAi (- Dox, 72 hrs)
+shRNAi (+ Dox, 72 hrs)

D

30_{\text{M}} \left [ ^{14}\text{C}\right ] \text{6-MP Uptake (pmol/L)}

- Dox (72 hrs)  + Dox (72 hrs)

E

Cell Viability (%)

SLC43A3-HEK293 cells
SLC43A3-HEK293 +shRNAi (- Dox, 72 hrs)
SLC43A3-HEK293 +shRNAi (+ Dox, 72 hrs)

Log [6-MP] (M)
Figure 8

A. Western blot analysis of α-ENBT1 and α-β-Actin for control and SLC43A3 shRNAi treated cells.

B. Initial rate of [14C]6-mercaptopurine (6-MP) uptake. Treatment with SLC43A3 shRNAi increases the uptake of 6-MP.

C. 6-MP cytotoxicity analysis. SLC43A3 shRNAi treatment decreases cell viability.

D. Relative mRNA expression of genes involved in 6-mercaptopurine metabolism in control and SLC43A3 shRNAi treated cells. Higher expression of certain genes indicates increased activity or transcription of these genes.